Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

224.44
+2.951.33%
Post-market: 224.440.00000.00%19:59 EST
Volume:8.15M
Turnover:1.83B
Market Cap:540.74B
PE:20.35
High:225.50
Open:222.00
Low:220.70
Close:221.49
52wk High:225.50
52wk Low:141.50
Shares:2.41B
Float Shares:2.40B
Volume Ratio:0.73
T/O Rate:0.34%
Dividend:5.14
Dividend Rate:2.29%
EPS(TTM):11.03
EPS(LYR):11.03
ROE:35.56%
ROA:8.26%
PB:6.82
PE(LYR):20.34

Loading ...

US names HIV, arthritis drugs for next Medicare price talks

Reuters
·
3 hours ago

BRIEF-CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program

Reuters
·
4 hours ago

Darzalex Faspro®-Based Quadruplet Regimen Approved in the U.S. for Newly Diagnosed Patients With Multiple Myeloma Who Are Transplant Ineligible

THOMSON REUTERS
·
5 hours ago

Johnson & Johnson's Darzalex Faspro Approved by FDA for Multiple Myeloma

MT Newswires Live
·
5 hours ago

BRIEF-FDA Approves Daratumumab And Hyaluronidase-Fihj With Bortezomib, Lenalidomide, And Dexamethasone For Newly Diagnosed Multiple Myeloma

Reuters
·
6 hours ago

FDA Approves Daratumumab and Hyaluronidase-Fihj With Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma

THOMSON REUTERS
·
6 hours ago

Johnson & Johnson call volume above normal and directionally bullish

TIPRANKS
·
7 hours ago

Johnson & Johnson Is Maintained at Hold by Freedom Capital Markets

Dow Jones
·
7 hours ago

Siegfried To Acquire High-Quality Small Molecules Drug Substance Capacity In The Us

Reuters
·
Yesterday

Siegfried Acquires US Drug Substance Sites from Noramco Group and Extractas Bioscience

Reuters
·
Yesterday

Perrigo Co. PLC Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Yesterday

The North American Income Trust plc publishes presentation outlining portfolio strategy and performance highlights

Reuters
·
Yesterday

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Adagene (ADAG) and Johnson & Johnson (JNJ)

TIPRANKS
·
Jan 26

Argus Raises Price Target on Johnson & Johnson to $240 From $210

MT Newswires Live
·
Jan 24

Johnson & Johnson Stock Trending Higher Among Analysts

TIPRANKS
·
Jan 23

Johnson & Johnson Reports Modest Q4 Beat but Stock Seems Fairly Valued, Morgan Stanley Says

MT Newswires Live
·
Jan 23

Johnson & Johnson price target raised to $265 from $230 at Scotiabank

TIPRANKS
·
Jan 22

Johnson & Johnson Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
Jan 22

Johnson & Johnson price target raised to $250 from $222 at TD Cowen

TIPRANKS
·
Jan 22

Johnson & Johnson price target raised to $250 from $240 at Goldman Sachs

TIPRANKS
·
Jan 22